相关实验视频

Updated: Jun 27, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

药物治疗不可治疗的:在固体瘤中准KRAS信号的进展

Prajna Tripathi¹, Rajni Kumari², Rajiv Pathak³

¹Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, United States.

International review of cell and molecular biology

|April 25, 2024

概括

向疗法正在彻底改变癌症治疗,特别是在肺癌,胰腺癌和结肠癌中常见的基尔斯鼠肉瘤病毒瘤同类基因 (KRAS) 突变中. 最近的进展为这些以前"不可抗药"的目标提供了新的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

癌症是全球首要的死亡原因,基尔斯大鼠肉瘤病毒瘤同类基因 (KRAS) 突变导致了大量固体瘤.
在肺癌,胰腺癌和结肠癌中普遍存在的KRAS突变与预后不佳和生存率降低有关.
从历史上看,KRAS一直被认为是KRAS.

研究的目的:

为提供KRAS突变特征在固体瘤中的概述.
突出了解KRAS免疫微环境的进展,并开发KRAS驱动的小鼠模型.
审查针对KRAS突变癌症的向治疗方法的近期进展.

主要方法:

针对癌症向治疗的生物化学和技术进步的文献综述.
对KRAS驱动癌症中瘤免疫微环境的研究分析.
检查临床前模型,包括KRAS驱动的小鼠.
综合目前针对特定KRAS突变的治疗策略.

主要成果:

针对KRAS突变癌症的向疗法在过去十年中取得了重大突破.
对KRAS生物学及其在癌症发展中的作用的理解已经大大进步.
正在探索新的治疗策略,以克服针对KRAS的挑战.

结论:

向疗法代表了治疗KRAS突变癌症的范式转变.
对免疫微环境,临床前模型和特定的KRAS突变向疗法的持续研究至关重要.
对KRAS信号和治疗发展的全面理解有可能改善固体瘤患者的治疗结果.

关键词:

克拉斯抑制剂是克拉斯抑制剂.在KRAS突变中发生突变.用KRAS驱动的小鼠模型.通过KRAS介导的信号通道.固体瘤是一种固体瘤.治疗策略治疗策略瘤微环境是一个微环境.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Small GTPases - Ras and Rho

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...